March 30, 2016

Biocept Forms Clinical Advisory Board of World-Renowned Oncologists

Key Opinion Leaders to Advise on Expanding Adoption of Biocept's Liquid Biopsy Tests

SAN DIEGO, March 30, 2016 /PRNewswire/ -- More than 1.5 million new cancer cases are expected to be diagnosed in 2016, according to the American Cancer Society. To further its mission of improving outcomes for the millions of people who battle cancer each year, Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with proven liquid biopsy technology for cancer profiling and monitoring, announces the formation of a Clinical Advisory Board. The Clinical Advisory Board is comprised of leading oncologists with diverse specialties to provide guidance on expanding Biocept's physician customer base and support useage of Biocept's liquid biopsy tests.

"We have created some of the most advanced blood-based technology for profiling and monitoring cancer and, as we grow, we are continually seeking ways to increase the use of our tests in the clinical setting," said Biocept SVP and Senior Medical Director Veena Singh, MD. "By enlisting the expertise of the highly talented physicians joining our Clinical Advisory Board, we can call on their first-hand knowledge to help us better understand our clients' needs."

Members of the Biocept Clinical Advisory Board are as follows:

- **Jenny Chang, MD** - Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Dr. Chang is world-renown for her work in clinical research.
- **Michael Kosty, MD** - Medical Director of the Cancer Center at Scripps Clinic and Scripps Green Hospital in La Jolla, Calif., Dr. Kosty is a seasoned hematologist and oncologist who has specialized in lung and prostate cancer for nearly 20 years.
- **Edgardo S. Santos, MD, FACP** - Medical Director of Cancer Research and co-leader of the Thoracic and Head & Neck Cancer programs at The Eugene M. & Christine E. Lynn Cancer Institute of Boca Raton Regional Hospital in Boca Raton, Florida. Dr. Santos also serves on the staff of several hospitals in the area.
- **Lee S. Schwartzberg, MD, FACP** - Executive Director Medical Oncologist and Hematologist at the University of Tennessee's West Cancer Center in Memphis, Dr. Schwartzberg is an award-winning oncologist who has published more than 150 articles in peer-reviewed journals.

"Establishing a Clinical Advisory Board is among the priorities we set for 2016 and it is gratifying to have these highly respected practicing physicians and academic leaders join this newly formed group," added Biocept President and CEO Michael W. Nall. "This group has a keen understanding of the molecular oncology space and how our tests are being used in a clinical setting that will help guide us in multiple aspects of our business as liquid biopsy is moved to standard of care."

About Biocept
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers assays for prostate cancer, gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated tests for other solid tumors in the near term. For additional information, please visit www.biocept.com.

Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements

and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the number of cancer cases diagnosed in 2016, our ability to improve outcomes for cancer patients and enhance individual treatments of cancer, our ability to expand our physician customer base and support usage of our liquid biopsy tests, and our plans to introduce CLIA-validated tests for other solid tumors in the near term, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO